SCHEMBL5545685

SCHEMBL5545685

[CH2]c1ccccc1NCc1ccc(C)cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
GAA P10253 6/20 0.46
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
USP2 O75604 1/20 0.44
CASP1 P29466 1/20 0.44
HBB P68871 1/20 0.44
HTT P42858 1/20 0.41
LMNA P02545 3/20 0.40
MAPK1 P28482 3/20 0.39
TP53 P04637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 2/20 0.38
TNF P01375 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541429 0.87 GAA (0.49) MAPTSMN1; SMN2NPC1RAB9AGAA
SCHEMBL688010 0.83 MAPT (0.53) MAPTSMN1; SMN2GAAALDH1A1KDM4E
SCHEMBL5542074 0.80 MAPT (0.40) MAPTSMN1; SMN2NPC1RAB9AGAA
SCHEMBL5542578 0.76 HTT (0.52) MAPTSMN1; SMN2NPC1RAB9AGAA
SCHEMBL5544368 0.75 MAPT (0.58) MAPTSMN1; SMN2GAAALDH1A1KDM4E
SCHEMBL5545641 0.75 BRD4 (0.46) MAPTNPC1RAB9AALDH1A1KDM4E
SCHEMBL5544031 0.75 ADRA2C (0.41) MAPTSMN1; SMN2GAAALDH1A1KDM4E
SCHEMBL5538928 0.73 CYP3A4 (0.48) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL5544240 0.72 LMNA (0.47) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL6491880 0.72 HDAC8 (0.43) MAPTSMN1; SMN2NPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885SMN1; SMN2 3985/4885NPC1 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.